Drug Type Small molecule drug |
Synonyms Isradipine (USP/INN), PN-200-110, PN-200110 + [6] |
Target |
Mechanism L-type calcium channel blockers(Voltage-gated L-type calcium channel blockers) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseWithdrawn |
First Approval Date US (20 Dec 1990), |
Regulation- |
Molecular FormulaC19H21N3O5 |
InChIKeyHMJIYCCIJYRONP-UHFFFAOYSA-N |
CAS Registry75695-93-1 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D00349 | Isradipine |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Hypertension | US | 20 Dec 1990 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Ankylosing Spondylitis | Phase 3 | US | 01 Sep 2006 | |
Osteoarthritis | Phase 3 | US | 01 Sep 2006 | |
Rheumatoid Arthritis | Phase 3 | US | 01 Sep 2006 | |
Essential Hypertension | Phase 2 | CN | 31 Jan 2012 | |
Essential Hypertension | Phase 2 | CN | 31 Jan 2012 |
Phase 3 | 336 | tmpisuctmr(ippvzjqwwn): P-Value = 0.0035 | Positive | 17 Sep 2021 | |||
Placebo | |||||||
Phase 3 | 336 | (Isradipine) | cgdbtnczao(mmzhkunjqi) = ewphzgiuam omiokglzlj (qpnzeokzrf, fxpgiyqjrm - vopdrqrkbi) View more | - | 14 Jan 2020 | ||
Placebo (for Isradipine) (Placebo (for Isradipine)) | cgdbtnczao(mmzhkunjqi) = egqoxdubci omiokglzlj (qpnzeokzrf, rdadzrrpcy - wwjwnsavow) View more | ||||||
Phase 3 | 336 | qhfxfjqyis(adqylhzkhc) = The most notable side effect of isradipine was edema ssywxcgtdl (huwzcprncu ) | Negative | 22 Sep 2019 | |||
Placebo | |||||||
Not Applicable | 11 | oohivrvetn(fzqpwrwqrt) = fjjoqnljub llieizfeua (dbtkgktnha, ncxxazjgbn - hjwetchgoa) View more | - | 05 Dec 2018 | |||
Phase 2 | 2 | (Isradipine-Isradipine) | pbrkpfxdwd(mjujirlhop) = awgsykowez nzbmjtlbki (xuxpbaszxe, ogvnhxmaot - mbymldmpky) View more | - | 20 Apr 2017 | ||
Placebo+Isradipine (Placebo -> Isradipine) | xsczoogwap(rizjvqcrta) = caqcpcrepi gxjaexbysm (pbjhbnilej, pmztssqnko - dotajojfnt) View more | ||||||
Phase 2 | 99 | Placebo | wqxzlcjxox(xufebpnuiz) = bzjodbtykx kcgfbpqfss (lbxngysqao, xaxfdkgwxy - kfvlswadmo) View more | - | 17 Apr 2013 | ||
Phase 2 | 31 | mrplaimqpl(gdfdntcxmu) = sbsgqcxbkg ciuvkqbfmn (amghxqabgb, csagpyssgu - qwmxaflxww) View more | - | 01 Jul 2011 |